Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

173
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
173
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

801
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
801
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

294
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
294
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

804
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
804
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

1.3K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
1.3K
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

870
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
870

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mindful diagnostics in culture-negative endocarditis: early noninvasive diagnosis of <i>Tropheryma whipplei</i> by plasma microbial cell-free DNA.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Rethinking flow: the paradox of renoprotection without increased renal blood flow in cardiopulmonary bypass.

Journal of thoracic disease·2026
Same author

Warm ischemic time-dependent effects on oxidative stress, endoplasmic reticulum stress, and inflammation in cold storage human donor hearts.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Predicting Sepsis in Heart Failure Patients Supported by Left Ventricular Assist Devices: The Role of VE-Cadherin and ADAM10.

International journal of molecular sciences·2026
Same author

Management of Dialysis for Patients Receiving Mechanical Circulatory Support.

Journal of the American Society of Nephrology : JASN·2026
Same author

Changes in Vascular Cell Adhesion Molecule-1 in Conventional Versus Robotic Bypass Graft Surgery.

The Journal of surgical research·2026
Same journal

Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.

Kidney international reports·2026
Same journal

Association of IgG N-Glycans With Adverse Outcomes in CKD.

Kidney international reports·2026
Same journal

Urinary Soluble CD163: A Dynamic Biomarker for Monitoring Treatment Response and Relapse in IgA Nephropathy.

Kidney international reports·2026
Same journal

<i>APOL1</i> Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

Kidney international reports·2026
Same journal

Validation of the Standardized Outcomes in Nephrology - Life Participation (SONG-LP) Instrument in People Receiving Dialysis.

Kidney international reports·2026
Same journal

Effect of Hemodialysis With Citrate on Vascular Calcification.

Kidney international reports·2026
查看所有相关文章

相关实验视频

Updated: Jan 14, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

2.0K

功能轨迹与机械循环支持的功能轨迹

Carl P Walther1, Harveen K Lamba2, Ajith P Nair3,4

  • 1Section of Nephrology, Department of Medicine, Selzman Institute for Kidney Health, Baylor College of Medicine, Houston, Texas, USA.

Kidney international reports
|October 27, 2025
PubMed
概括
此摘要是机器生成的。

在左心室辅助装置 (LVAD) 植入后,功能表现出明显的早期和晚期阶段. 这些阶段,以及断点,与患者的因素和存活率有关,有助于理解不良结局.

关键词:
在LVAD和LVAD之间.美国GFRGFR脏 脏 脏是什么?机械循环支持 机械循环支持飞行轨道的轨迹是什么

更多相关视频

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.9K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K

相关实验视频

Last Updated: Jan 14, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

2.0K
Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.9K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K

科学领域:

  • 心脏病学 心脏病学
  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 生物医学工程 生物医学工程

背景情况:

  • 在左心室辅助器件 (LVAD) 接受者中,脏不良结果很常见,但人们对其了解甚少.
  • 基于肌素的估计膜过率 (eGFR) 用于评估功能,但具有不确定的有效性和LVAD后的非线性变化.

研究的目的:

  • 在LVAD植入后90天内调查非线性eGFR轨迹.
  • 探索eGFR轨迹参数,患者因素和临床结果之间的关系.

主要方法:

  • 使用了两个队列:一个单中心 (n=190) 和一个美国国民 (n=10794) LVAD接受者队列.
  • 采用了带有两个段的细分线性回归来建模eGFR轨迹,并与其他模型进行比较.
  • 评估了轨迹参数与患者因素和临床结果的关联.

主要成果:

  • 分段线性回归提供了最合适的方法,识别了早期/晚期斜率,断点时间和断点eGFR.
  • 女性性别和年龄较大等患者因素与晚期轨迹斜率有关.
  • 所有四个轨迹参数与生存相关;在调整后,断点eGFR和晚期斜率仍然显著.

结论:

  • 植入LVAD后的功能遵循双相轨迹 (有断点的早期/晚期线性阶段).
  • 这些轨迹指标与生存和植入前因素相关.
  • 识别的指标可以为LVAD患者的不良脏结果和干预措施的研究提供信息.